9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers

9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers

Testicular germ cell tumours (TGCTs) represent approximately 1% of all male neoplasms and 5% of urological malignancies, yet they are the single most common solid malignancy diagnosed in young adult males aged 15 to 35 years. Marked epidemiological variation exists globally, with Northern European nations (such as Denmark, Norway, and Switzerland) demonstrating the highest worldwide incidence (>10 cases per 100,000 men per year), whereas African and Asian populations exhibit significantly lower rates. Despite a rising worldwide incidence over recent decades, TGCT remains one of the greatest success stories of modern urological oncology: overall 5-year cancer-specific survival exceeds 95% across all clinical stages due to accurate histological subtyping, precise serum marker kinetics, early cross-sectional staging, and extreme sensitivity to cisplatin-based systemic polychemotherapy.

---

1. Pathogenesis, Genetics & Risk Factors

TGCTs arise from primordial germ cells that fail to differentiate normally during embryonic development. Gain of chromosome 12p is a characteristic alteration of postpubertal GCNIS-related tumours, often as isochromosome 12p [i(12p)] or other 12p amplification, involving genes such as CCND2 and KRAS.

Several well-established risk factors contribute to the oncogenesis of testicular germ cell tumours:

• Cryptorchidism (Undescended Testis): Represents the strongest clinical risk factor, conveying a 4- to 8-fold increased relative risk of malignant transformation. The relative risk is highest for intra-abdominal testes (~10-fold) compared to inguinal or canalicular locations. Surgical orchidopexy performed prior to puberty—ideally between 6 and 12 months of age—optimizes germ cell maturation, partially mitigates malignant risk, and positions the gonad within the scrotum to facilitate regular self-examination. Crucially, up to 20% of tumours in patients with a history of unilateral cryptorchidism develop in the contralateral, normally descended testis, confirming an underlying bilateral gonadal dysgenesis.
• Testicular Dysgenesis Syndrome (TDS): Formulated by Skakkebaek, this unifying hypothesis proposes that cryptorchidism, hypospadias, subfertility/impaired spermatogenesis, and germ cell tumours share a common developmental origin stemming from disturbed embryonic Sertoli and Leydig cell development during fetal life, often precipitated by genetic factors and intrauterine exposure to environmental endocrine-disrupting chemicals.
• Personal and Family History: A personal history of TGCT carries a 2% to 5% cumulative risk of developing a metachronous or synchronous malignancy in the contralateral testis over 25 years. A family history in a first-degree relative strongly increases risk: having an affected brother increases risk 8- to 10-fold, whereas having an affected father increases risk 4-fold, pointing to complex polygenic inheritance.
• Klinefelter Syndrome (47,XXY): Associated with primary testicular hypogonadism, elevated serum gonadotropins, and azoospermia. Importantly, Klinefelter syndrome is strongly predisposing to primary mediastinal non-seminomatous germ cell tumours (PMNSGCT), rather than gonadal testicular tumours.

---

2. Clinical Presentation & Physical Examination

The classic clinical presentation of testicular cancer is a painless, firm, non-tender, discrete intratesticular swelling, nodule, or enlargement discovered incidentally by the patient during bathing or by a sexual partner. Approximately 20% to 30% of patients report a vague, dull ache, heaviness, or dragging sensation in the scrotum or lower abdomen.

Key clinical variations and emergency presentations include:

• Acute Scrotal Pain (~10%): Occurs secondary to rapid intratumoural hemorrhage, capsular distension, central ischemic necrosis, or concurrent epididymo-orchitis, frequently mimicking acute testicular torsion.
• Metastatic Symptoms (~10–15%): Presenting complaints may stem from distant metastases rather than the primary intrascrotal mass: lumbar back pain from bulky retroperitoneal lymphadenopathy, flank pain from ureteral obstruction, lower extremity deep venous thrombosis from inferior vena cava compression, dyspnea, hemoptysis, or cough from extensive pulmonary metastases, or supraclavicular lymphadenopathy (Virchow's node).
• Endocrine Manifestations (~5%): Bilateral gynecomastia and loss of libido may occur due to trophoblastic production of human chorionic gonadotropin (beta-hCG), which cross-reacts with LH receptors on Leydig cells, stimulating excessive estradiol synthesis and disrupting the androgen-to-estrogen ratio.

---

3. Scrotal Ultrasonography & Diagnostic Workup

High-resolution scrotal ultrasonography utilizing a high-frequency 10 to 14 MHz linear-array transducer is mandatory whenever a testicular lesion is suspected. Scrotal ultrasound exhibits a diagnostic sensitivity of >95% to 100% and reliably distinguishes intratesticular from extratesticular pathology:

• Intratesticular Lesions: A palpable solid intratesticular mass is highly suspicious for malignancy, but many small, non-palpable incidental lesions are benign. Malignancy typically manifests as a well-defined or lobulated hypoechoic intratesticular mass displaying architectural heterogeneity, microcalcifications, and distinct internal vascularity on color Doppler.
• Extratesticular Lesions: Masses arising within the epididymis, spermatic cord, or tunica vaginalis (e.g., epididymal cysts, spermatoceles, hydroceles, adenomatoid tumours) are usually benign; suspicious solid lesions still require appropriate assessment.

Essential Preoperative Workup

Before undertaking any surgical manipulation, three mandatory preparatory steps must be performed:

1. Preoperative Serum Tumour Markers: Serum concentrations of AFP, beta-hCG, and LDH must be sampled immediately before orchiectomy to establish baseline values for postoperative kinetic monitoring and UICC S-staging.
2. Reproductive Counselling & Sperm Banking: Every reproductive-age male diagnosed with a testicular tumour must receive formal fertility counselling. Semen analysis and cryopreservation (sperm banking) should be actively offered prior to orchiectomy or any subsequent gonadotoxic systemic therapy or retroperitoneal lymphadenectomy.
3. Endocrine Profiling: Baseline serum testosterone, LH, and FSH levels are measured to assess preexisting gonadal hypofunction.

---

4. Inguinal Orchiectomy: Technique & Strict Boundaries

Radical inguinal orchiectomy is the standard diagnostic and initial therapeutic procedure for suspected TGCT. Selected small indeterminate lesions or bilateral/solitary-testis tumours may permit expert testis-sparing surgery with frozen section; life-threatening metastatic disease may require chemotherapy first. The operation must follow rigorous oncological principles:

1. Inguinal Incision: An oblique skin incision is made 2 cm superior and parallel to the inguinal ligament, extending from the internal ring to the pubic tubercle.
2. Cord Control (Early Cross-Clamping): The external oblique aponeurosis is incised, and the spermatic cord is isolated at the level of the deep internal inguinal ring. An atraumatic vascular clamp (e.g., soft Romney clamp) is placed across the entire spermatic cord BEFORE manipulating, delivering, or inspecting the testis. Early proximal cord occlusion interrupts arterial inflow, pampiniform venous drainage, and lymphatic egress, providing proximal vascular control during surgical mobilization.
3. Testicular Delivery & Cord Ligation: The testis is delivered into the surgical field within its intact tunica vaginalis. If malignancy is confirmed, the spermatic cord is doubly ligated with non-absorbable heavy sutures and divided high at the level of the deep internal ring.

---

5. Serum Tumour Markers & Clearance Kinetics

Serum tumour markers play an indispensable role in the diagnosis, histological discrimination, staging, prognosis, and post-therapeutic surveillance of testicular neoplasms. The three classic biomarkers are Alpha-fetoprotein (AFP), beta-Human Chorionic Gonadotropin (beta-hCG), and Lactate Dehydrogenase (LDH).

Alpha-Fetoprotein (AFP)

• Biological Origin: Major fetal serum glycoprotein synthesized by the embryonic yolk sac, fetal liver, and gastrointestinal tract.
• Elimination Half-Life: 5 to 7 days.
• Clinical Significance: Elevated in yolk sac tumours and embryonal carcinomas. Crucially, AFP is NEVER produced by pure seminoma cells. Significantly raised AFP unexplained by another cause in a tumour reported as pure seminoma suggests an occult non-seminomatous component. Seek expert pathology review and manage as NSGCT; modest stable elevations require assessment before treatment.
• Confounders: False-positive elevations occur in hepatocellular carcinoma, acute or chronic viral hepatitis, cirrhosis, gastric/pancreatic carcinoma, and ataxia telangiectasia.

Beta-Human Chorionic Gonadotropin (beta-hCG)

• Biological Origin: Heterodimeric glycoprotein hormone; shares a common alpha-subunit with LH, FSH, and TSH, but possesses a distinct beta-subunit that conveys immunogenic specificity. Secreted by syncytiotrophoblasts.
• Elimination Half-Life: 24 to 36 hours (1.0 to 1.5 days).
• Clinical Significance: Universally and massively elevated in choriocarcinoma (often >50,000 to >1,000,000 IU/L); moderately elevated in ~50% of embryonal carcinomas; and mildly elevated in 15% to 20% of pure seminomas (typically <200–500 IU/L, arising from scattered syncytiotrophoblastic giant cells without altering the clinical behaviour of seminoma).
• Confounders: Unexpected elevations require repeat assessment for pituitary hCG in hypogonadism or assay interference (including heterophile antibodies). Cannabis-associated elevations have been reported, but an unexpected result must not simply be attributed to drug use.

Lactate Dehydrogenase (LDH)

• Biological Origin: Ubiquitous cytoplasmic glycolytic enzyme whose elevation reflects tumour volume, cellular proliferation rate, and tissue necrosis.
• Kinetic Interpretation: LDH level, rather than an assumed single half-life, is used in staging and prognosis.
• Clinical Significance: Non-specific marker elevated in both seminoma and non-seminoma; directly integrated into the UICC/AJCC S-staging and IGCCCG risk stratification algorithms.
• Confounders: Hemolysis, acute myocardial infarction, muscle injury, and acute hepatic injury.

Post-Orchiectomy Kinetic Decay Monitoring

Following radical orchiectomy, serial marker determinations must be performed until normal levels are reached. Persistent or rising AFP/hCG after expected decay suggests metastatic disease even with normal CT. Confirm the trend and exclude alternative causes, especially with low stable values; a single slow decline does not prove metastasis. Normal markers also do not exclude metastatic disease.

---

6. Germ Cell Neoplasia In Situ (GCNIS / TIN)

Germ Cell Neoplasia In Situ (GCNIS), formerly termed Testicular Intraepithelial Neoplasia (TIN), is the common pre-invasive precursor cell for all postpubertal testicular germ cell tumours (both seminomas and non-seminomas), with the exception of spermatocytic tumours and pediatric prepubertal teratomas/yolk sac tumours. Histologically, atypical large gonocytes with hyperchromatic nuclei, prominent nucleoli, and clear glycogen-rich cytoplasm align along the basement membrane of seminiferous tubules. Immunohistochemically, GCNIS cells express OCT3/4, SALL4, c-KIT (CD117), PLAP, and D2-40 (podoplanin).

Indications for Contralateral Testicular Biopsy

The baseline incidence of GCNIS in the contralateral testis of patients with unilateral TGCT is approximately 5% to 9%. Routine contralateral biopsy in all patients remains controversial; however, discuss the benefits and risks of biopsy in high-risk patients, especially:

• Testicular volume <12 mL, and/or
• History of cryptorchidism.

Biopsy is unnecessary in men >40 without risk factors; young age alone is not an automatic indication.

Risk is increased in these patients, but a negative biopsy does not eliminate future tumour risk. When performed, a two-site open surgical incision biopsy is recommended to maximize diagnostic sensitivity and avoid sampling error.

Therapeutic Management of GCNIS

If untreated, approximately 50% of GCNIS cases progress to invasive testicular cancer within 5 years, and 70% within 7 years. Clinical options include:

1. Close Observation: An option after counselling; fertile men may defer treatment while pursuing paternity, with regular self-examination and ultrasound.
2. Local Radiotherapy: In a solitary testis, consider 18–20 Gy in 2-Gy fractions. It is highly effective but causes infertility through germ-cell depletion and increases long-term Leydig insufficiency risk; monitor endocrine function.
3. Orchiectomy: An option particularly when the opposite testis is normal. Chemotherapy does not reliably eradicate isolated GCNIS.

---

7. UICC/AJCC TNM Staging, S-Stage & Retroperitoneal Anatomy

Accurate staging requires contrast-enhanced CT of the chest, abdomen, and pelvis (CECT CAP) to evaluate the retroperitoneal nodal landing zones and screen for pulmonary and visceral metastases.

Retroperitoneal Lymphatic Landing Zones

Testicular lymphatic drainage strictly mirrors embryonic vascular development:

• Right Testis: Primary lymphatic drainage lands in the interaortocaval, precaval, and paracaval lymph nodes, situated between the right renal vein and the aortic bifurcation.
• Left Testis: Primary lymphatic drainage lands in the left para-aortic (periaortic) and preaortic lymph nodes at the level of the left renal vein (L2 vertebrae).
• Crossover Pattern: Lymphatic flow demonstrates predictable asymmetry: right-to-left crossover occurs readily from the interaortocaval space to the left para-aortic region. Left-to-right crossover is less common but cannot be excluded; drainage patterns guide templates without guaranteeing confinement to one side.

---

Tumour Marker Kinetics & UICC/AJCC S-Staging Classification

Pathological nodes additionally consider count and extranodal extension: pN1 requires ≤5 involved nodes, none >2 cm; pN2 includes a mass >2–5 cm, >5 involved nodes (none >5 cm), or extranodal extension; pN3 requires a mass >5 cm. For serum markers, assign the highest category reached by any marker: S1 requires all below S2 thresholds but at least one above normal; S2/S3 require any marker in that range. Base S on postoperative values after expected decay. Clinical and pathological N rules must not be mixed.